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CASE  REPORT
Introduction
Nonalcoholic fatty liver disease (NAFLD) is defined
as fat accumulation in the liver exceeding 5–10% of
total liver weight in nonalcohol users.1 It comprises a
wide variety of histologic findings, from steatosis,
inflammation, hepatocyte ballooning and sinusoidal
fibrosis, to polymorphonuclear cell infiltrates with or
without Mallory hyaline body. Causes of NAFLD
are obesity, diabetes mellitus (DM), hyperlipidemia,
drugs, parenteral nutrition, gastric bypass surgery, and
inherited metabolic disorders.2 In Western countries,
20–30% of adults have excess fat accumulation in
the liver.1 It may progress to fibrosis, cirrhosis, and
hepatocellular carcinoma.3 NAFLD is common in
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Taiwan and this disease is usually considered benign
without crucial clinical significance.4 NAFLD-related
cirrhosis has rarely been reported in Taiwan. We
herein report an obese patient with type 2 DM who
had nonalcoholic fatty liver cirrhosis (NAFLC) with
bleeding esophageal varices (EV) as the first clinical
manifestation.
Case Report
A 41-year-old male was brought to our emergency
department because of hematemesis and passage of
tarry stool for 1 day. He had no history of hepatitis,
alcohol drinking, blood transfusion, chemical solvent
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exposure, drug abuse, or herbal medicine intake. He
had type 2 DM, having been treated with glucophage
and glimepiride for 4 years, and had blood glucose
levels controlled in an acceptable range. He weighed
102.5 kg and had a body height of 175.5 cm; thus,
the body mass index (BMI) was 33.3 kg/m2. In recent
years, his serum transferase levels were found to reach
1–2 times the upper limit of normal range. On physical
examination, the patient appeared robust and in acute
distress. Lungs, heart, abdomen, arms, and legs were
unremarkable. Mild palmar erythema was noted.
However, there was no evident spider angioma,
gynecomastia, or ascites.
On admission, his serum levels were as follows:
alanine aminotransferase (ALT), 48 U/L (normal,
0–40 U/L); aspartate aminotransferase (AST) 48 U/L
(normal, 5–45 U/L); total bilirubin 1.0 mg/dL
(normal, 0.2–1.6 mg/dL); alkaline phosphatase
70 U/L (normal, 30–70 U/L); gamma-glutamyl
transpeptidase 110 (normal, 8–60 U/L); albumin
3.7 g/dL (normal, 3.7–5.3 g/dL); globulin 2.4 g/dL
(normal, 2.7–3.1 g/dL); cholesterol 167 mg/dL
(normal, 125–240 mg/dL); triglyceride 75 mg/dL
(normal, 20–200 mg/dL); high-density lipoprotein
79 mg/dL ( normal, 30–70 mg/dL); low-density
lipoprotein 97 mg/dL (normal, < 160 mg/dL);
prothrombin time 13.9 seconds, fasting glucose 153
mg/dL (normal, 65–115 mg/dL); 2 hours post-
prandial glucose 179 mg/dL (normal, <140 mg/dL);
and HbA1c 6.0% (normal, 4.5–6.2%). His fasting
serum cortisol, free T4, and thyroid-stimulating
hormone were in the normal range. The blood white
cell count was 2,900/mm3, hemoglobin 10.6 g/dL,
and platelet 76,000/mm3. Viral hepatitis markers
were all negative, including hepatitis B surface antigen,
anti-hepatitis C antibody, anti-Epstein Barr virus
immunoglobulin M (IgM), anti-cytomegalovirus
IgM, and anti-herpes simplex virus IgM. Hepatitis B
virus DNA (Amplicor HBV Monitor Test, Roche
Diagnostics, Pleasanton, CA, USA; sensitivity 1,000
copies/mL) and hepatitis C virus RNA (Amplicor
HCV Monitor Test, Roche Diagnostics; sensitivity
600 IU/mL) were undetectable. The immunologic
tests, including antinuclear antibody, anti-smooth
muscle antibody, and anti-mitochondrial antibody,
were all negative. His serum ferritin and ceruloplasmin
levels were in the normal range of 115 ng/mL (normal,
38–280 ng/dL) and 31.9 mg/dL (normal, 22–58
mg/dL), respectively. An emergency pan-endoscopy
examination was then done and revealed 4 EV (3F1
and 1F2) with positive red-color sign and portal
hypertensive gastropathy. EV ligation (EVL) was
effective.
Both computed tomography and abdominal
sonogram revealed a typical fatty liver, an uneven
surface of the liver, collateral circulation, and
splenomegaly. A liver needle biopsy was performed,
which disclosed liver cirrhosis (F4), mild activity
(A1), and moderate fatty change (Figure 1). The mild
activity (A1) meant mild inflammation (necrosis or
inflammation cell infiltration in focal lobular area,
or limited to the portal area only). The pathologic
findings showed the typical findings of NAFLC:
Mallory’s body, sinusoidal and pericellular fibrosis,
neutrophilic infiltration, macrovesicular fatty
changes, septal fibrosis, and regeneration nodules.
Furthermore, the immunohistochemical stain for
hepatitis B core antigen was negative in the liver
specimen. The patient was discharged uneventfully
14 days later.
Discussion
The patient presented here had type 2 DM and overt
obesity. The World Health Organization has defined
a BMI 25.0–29.9 kg/m2 as class I obesity and a BMI
higher than 30.0 kg/m2 as class II obesity for people
in the Asia-Pacific region.5 Accordingly, 24% (20.2%
of class I obesity and 3.8% of class II obesity) of
adults are overweight in Taiwan.4 Male sex, obesity,
hypertriglyceridemia, and hyperglycemia are factors
leading to fatty liver.4 The prevalence of fatty liver
and type 2 DM in the Taiwanese population is
36.9%6 and 13.4 %4, respectively. NAFLD is reported
to be present in 20–25% of obese patients, whereas
2–3% have cirrhosis in Western counties.7 In addition,
old age, obesity, and diabetes predict liver fibrosis
in NAFLD.1 Our patient had 2 risk factors: obesity
and diabetes.
In Farrell’s study, less than 2% of NAFLD is drug
related.8 The drugs well-known to induce NAFLD are
amiodarone, tamoxifen, and methotrexate.8 However,
the present case showed no such drug exposure history.
Some surgical procedures, including gastroplexy,
jejunoileal bypass, extensive small bowel resection,
and bilio-pancreatic diversion, may also result in
NAFLD.3 Our patient previously had none of these
procedures.
The majority of NAFLD patients are asymptomatic,
even at the stage of cirrhosis. Nevertheless, malaise,
fatigue, and right upper abdominal quadrant
discomfort, due to distension of the Glisson capsule,
may drive them to seek medical aid.9 Mild elevation of
serum transferase levels is one of the abnormal
laboratory tests in NAFLD patients.10,11 Usually, the
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serum ALT level is higher than the AST level. When
the AST/ALT ratio goes beyond 1, liver fibrosis or
cirrhosis should be suspected.12 In our patient, the
AST/ALT ratio was 1, which contributed little to the
diagnosis of liver cirrhosis.
The diagnosis of NAFLD is established by exclusion
of other possible liver diseases. Liver biopsy has been
the gold standard for diagnosis. Brunt et al13 proposed
a pathologic classification of NAFLD from grade 1
(simple steatosis) to 4 (Mallory’s hyaline or fibrosis
with portal inflammation). The prevalence of cirrhosis
is predominant in grades 3 and 4.14 Inflammation in
NAFLD is usually lobular, low grade, and with mixed
neutrophil and mononuclear cell infiltration. The liver
biopsy of our patient showed liver cirrhosis, severe
fibrosis, portal inflammation, Mallory’s body, and
moderate fatty change (Figure 1). These pathologic
findings were classified into grade 4.
The treatment of NAFLD is primarily to eliminate
or modulate risk factors. It includes body weight
control, adequate glycemic control in diabetic patients,
treatment of dyslipidemia, and discontinuation of
hepatotoxic medications. Weight reduction has proven
effective to improve liver histology and serum
aminotransferase in obese NAFLD patients.15 Our
patient was taught body weight reduction and
normalized glycemic control upon discharge.
With the increasing prevalence of obesity and DM
in Taiwan, numbers of patients with NAFLD are
expected to grow. NAFLD is usually thought to be
harmless and of little clinical significance. However,
this case reminds us that NAFLD can evolve into
severe liver disease, such as liver cirrhosis. Although
NAFLD with the first clinical manifestation of EV
bleeding, as in our patient, is rare, the mortality rate of
EV bleeding is high. Therefore, proper liver function
Figure 1. (A) Neutrophilic infiltration, ballooned hepatocytes, macrovesicular fatty change, and septal fibrosis (hematoxylin and eosin,
= 400). (B) Steatohepatitis with cirrhosis characterized by fibrotic bands around the regeneration nodule and cytoplasmic macrovesicle
fats (Masson trichrome, = 400). (C) Sinusoidal and pericellular fibrosis (Masson trichrome, = 1,600). (D) Mallory’s bodies (arrow;
hematoxylin and eosin, = 1,600).
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tests, blood cell counts, and abdominal sonography
surveillance are suggested in patients with morbid
obesity and long-term poorly controlled DM. Once
the AST/ALT ratio exceeds 1 or thrombocytopenia or
leucopenia is noted, pan-endoscopy examination is
recommended. If a large varix with red-color sign is
found, prophylactic EVL or administration of beta-
blockers may be considered to prevent EV bleeding.
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